SUBSCRIBE
SUBSCRIBE

Ayala Pharmaceuticals

IN THE PRESS
Pharm Country
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
May 9, 2024
 · 
1 min read
Pharm Country
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
March 26, 2024
 · 
2 min read
Business
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 20, 2024
 · 
4 min read
Drug Development
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 20, 2024
 · 
6 min read
Deals
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 6, 2024
 · 
8 min read
Drug Development
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala PharmaceuticalsAL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile
February 6, 2024
 · 
7 min read
Drug Development
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
November 6, 2023
 · 
7 min read
Pharm Country
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
October 23, 2023
 · 
13 min read
Deals
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
October 19, 2023
 · 
6 min read
JOBS